Tuesday, August 18, 2026
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0

View original at finance.yahoo.com
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0 Company Logo AI revolutionizes pharma manufacturing by enhancing efficiency, quality, and cost-effectiveness…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The market in Asia-Pacific is expected to grow at a higher CAGR during the forecast period driven by lower implementation costs, supportive government policies and rapidly expanding pharmaceutical sector

    80% confidence
  • The present market environment consists of approximately 130 participants including major, large, medium, and small enterprises

    80% confidence
  • Nearly 80% of firms are implementing machine learning to digitize various phases of the drug manufacturing process

    80% confidence
  • Over 95% of the companies involved in AI for drug production provide advanced software solutions

    80% confidence
  • The global AI in pharma manufacturing market size is estimated to grow from USD 1.20 billion in the current year to USD 34.7 billion by 2040, at a CAGR of 28% during the forecast period

    80% confidence
  • North America captures the majority of the market currently and this trend is unlikely to change in the future

    80% confidence
  • More than 60% of major pharmaceutical companies are utilizing AI to revolutionize their manufacturing processes

    80% confidence

Cited in these Via News reports